use of dronedarone for the preparation of a drug for the treatment of patients with arrhythmia and an increase in creatinine level due to dronedarone administration
A method of managing the risk of an increased morbidity and mortality in patients treated by an association of dronedarone and of at least a compound B selected from ACE inhibitors, angiotensin II receptor antagonists and potassium sparing diuretics which method comprises the following steps: a) initially measuring serum creatinine levels, which provides a reference level, b) monitoring serum creatinine levels at regular intervals during treatment of the patient by dronedarone and by the compound B, c) if the serum creatinine levels increases above the reference level, determining if the increase is due to dronedarone, to compound B or to another cause, d) if the increase in the serum creatinine level above the reference level is due to dronedarone, then the treatment with dronedarone and compound B can be pursued； if the increase in the serum creatinine level above the reference level is due to compound B, then the treatment with compound B may be interrupted； if the increase in the serum creatinine level above the reference level is due to another cause than administration of dronedarone or of compound B, then appropriate treatment of such another cause shall be undertaken, e) repeating steps b), c) and d) for the duration of the treatment with dronedarone and compound B.
